Proteomics International’s PromarkerD blood test has proven to be a step up from current tests in detecting patients at risk of diabetes-related kidney disease in a Perth-based study just published in an international peer-reviewed medical journal.
The company’s flagship PromarkerD biomarker-based diagnostic platform significantly outperformed the two standard methods of detecting a decline in kidney function in a community-based study of 857 adults diagnosed with type 2 diabetes.
